Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial

Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion

(2017) Shenghui He et al.   Science Translational Medicine

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation

(2017) Jiehui Deng et al.   Cancer Discovery

Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression

(2016) J. E. Bisi et al.   MOLECULAR CANCER THERAPEUTICS

Comprehensive genomic profiles of small cell lung cancer

(2015) Julie George et al.   NATURE

Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy

(2012) Patrick J. Roberts et al.   JNCI-Journal of the National Cancer Institute

Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition

(2010) Søren M. Johnson et al.   JOURNAL OF CLINICAL INVESTIGATION